James Keon

James Keon's lobbying: the registrations they file and every meeting they've reported since November 2021.

Registrant (responsible officer)

PRESIDENT

For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.

Former public offices

Acting Director General, Consumer Affairs, Industry Canada (1994–1994)
Regional Director, B.C. and Yukon, Consumer and Corporate Affairs (1991–1993)
Director, Intellectual Property, Consumer and Corporate Affairs (1988–1991)
Senior Analyst, Consumer Affairs, Consumer and Corporate Affairs (1987–1988)
Policy Analyst, Intellectual Property, Consumer and Corporate Affairs (1978–1986)
Research Analyst, Industry Statistics, Statistics Canada (1977–1978)

Meetings this Parliament: 17
Since Nov 2021: 56
Active registrations: 1

Registered for

Canadian Generic Pharmaceutical Association (CGPA)
Registered since Jun 23, 2025

56 meetings

Reported meetings

Sep 24, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Sven Schirmer · Senior Advisor, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more

Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.

Official report
Aug 12, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Raquel Dancho · Member of Parliament
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector. Read more

Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.

Official report
Apr 13, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more

Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.

Official report
Apr 2, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Martin Moen · Associate Assistant Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more

Provide input into the Canada-United States-Mexico Agreement (CUSMA).

Official report
Mar 30, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation. Read more

Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector.
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.

Official report
Mar 23, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Maggie Chi · Parliamentary Secretary to the Minister of Health
- Nora Draper · Parliamentary Secretary Assistant, Health Canada (HC)
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals. Read more

Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.

Official report
Mar 11, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector. Read more

Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.

Official report
Mar 10, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals. Read more

Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
Provide input into the Canada-United States-Mexico Agreement (CUSMA).

Official report
Mar 4, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Justine Frame · Policy Advisor, Health Canada (HC)
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals. Read more

Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.

Official report
Feb 10, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Marjorie Michel · Minister of Health, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more

Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.

Official report
Feb 3, 2026 Canadian Generic Pharmaceutical Association (CGPA)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Sven Schirmer · Senior Advisor, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more

Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.

Official report
Nov 27, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Margaret Zimmermann · Chief of Staff, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more

Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.

Official report
Sep 25, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals. Read more

Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Seeking harmonization of regulatory regimes and administrative processes nationally and internationally.
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.

Official report
Jul 29, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector. Read more

Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
Seeking harmonization of regulatory regimes and administrative processes nationally and internationally.

Official report
Jul 10, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Mélanie Joly · Minister of Industry and Minister Responsible for the Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
- Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation. Read more

Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.

Official report
Jun 25, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector. Read more

Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Health Canada with respect to user fees for therapeutic product regulatory programs.
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.

Official report
Jun 23, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Krista Urchenko · Senior Advisor, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more

Providing input with respect to the approval pathway for biosimilar medicines by Health Canada.
Health Canada with respect to user fees for therapeutic product regulatory programs.
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.

Official report
Apr 15, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Aaron Fowler · Chief Trade Negotiator and Associate Assistant Deputy Minister, Global Affairs Canada (GAC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more

Provide input into the Canada-United States-Mexico Agreement (CUSMA).

Official report
Mar 10, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Jeremy Bruce · Director, Canada-US Relations, Global Affairs Canada (GAC)
- Nicholas Lovrics · Senior Advisor, Parliamentary Affairs and Issues Management, Global Affairs Canada (GAC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more

Official report
Mar 10, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Eshan Naik · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more

Official report
Feb 27, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Eshan Naik · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more

Official report
Feb 5, 2025 Canadian Generic Pharmaceutical Association (CGPA)
- Mark Holland · Minister of Health, Health Canada (HC)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
- Linsey Hollett · A/Assistant Deputy Minister, Health Canada (HC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more

Official report
Nov 8, 2024 Canadian Generic Pharmaceutical Association (CGPA)
- Jade Mallette · Director of Parliamentary Affairs, Health Canada (HC)
Health Canada regarding the development of a national pharmacare strategy.

Official report
Nov 5, 2024 Canadian Generic Pharmaceutical Association (CGPA)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
Providing input with respect to the approval pathway for biosimilar medicines by Health Canada.

Official report
Oct 22, 2024 Canadian Generic Pharmaceutical Association (CGPA)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
Health Canada regarding the development of a national pharmacare strategy.

Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.